BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 16203770)

  • 1. Molecular alterations in primary prostate cancer after androgen ablation therapy.
    Best CJ; Gillespie JW; Yi Y; Chandramouli GV; Perlmutter MA; Gathright Y; Erickson HS; Georgevich L; Tangrea MA; Duray PH; González S; Velasco A; Linehan WM; Matusik RJ; Price DK; Figg WD; Emmert-Buck MR; Chuaqui RF
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6823-34. PubMed ID: 16203770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells.
    Singh AP; Bafna S; Chaudhary K; Venkatraman G; Smith L; Eudy JD; Johansson SL; Lin MF; Batra SK
    Cancer Lett; 2008 Jan; 259(1):28-38. PubMed ID: 17977648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
    Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
    Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profiles of androgen independent bone metastatic prostate cancer cells indicate up-regulation of the putative serine-threonine kinase GS3955.
    Bisoffi M; Klima I; Gresko E; Durfee PN; Hines WC; Griffith JK; Studer UE; Thalmann GN
    J Urol; 2004 Sep; 172(3):1145-50. PubMed ID: 15311059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
    D'Antonio JM; Ma C; Monzon FA; Pflug BR
    Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression.
    Salah Z; Maoz M; Cohen I; Pizov G; Pode D; Runge MS; Bar-Shavit R
    FASEB J; 2005 Jan; 19(1):62-72. PubMed ID: 15629896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
    Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
    Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcription factor and microRNA regulation in androgen-dependent and -independent prostate cancer cells.
    Wang G; Wang Y; Feng W; Wang X; Yang JY; Zhao Y; Wang Y; Liu Y
    BMC Genomics; 2008 Sep; 9 Suppl 2(Suppl 2):S22. PubMed ID: 18831788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
    Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.
    Holzbeierlein J; Lal P; LaTulippe E; Smith A; Satagopan J; Zhang L; Ryan C; Smith S; Scher H; Scardino P; Reuter V; Gerald WL
    Am J Pathol; 2004 Jan; 164(1):217-27. PubMed ID: 14695335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
    Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
    Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
    Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
    Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
    Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
    J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells.
    Margiotti K; Wafa LA; Cheng H; Novelli G; Nelson CC; Rennie PS
    Mol Cancer; 2007 Jun; 6():38. PubMed ID: 17553164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
    Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
    J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
    Cai Y; Lee YF; Li G; Liu S; Bao BY; Huang J; Hsu CL; Chang C
    Int J Cancer; 2008 Jul; 123(1):195-201. PubMed ID: 18386814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.
    Hååg P; Bektic J; Bartsch G; Klocker H; Eder IE
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):251-8. PubMed ID: 15982869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.